liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Future options of anti-angiogenic cancer therapy
Linköping University, Faculty of Medicine and Health Sciences. Linköping University, Department of Medical and Health Sciences, Division of Cardiovascular Medicine. Karolinska Institute, Sweden; University of Leicester, England; Glenfield Hospital, England.
2016 (English)In: CHINESE JOURNAL OF CANCER, ISSN 1000-467X, Vol. 35, no 21Article, review/survey (Refereed) Published
Resource type
Text
Abstract [en]

In human patients, drugs that block tumor vessel growth are widely used to treat a variety of cancer types. Many rigorous phase 3 clinical trials have demonstrated significant survival benefits; however, the addition of an anti-angiogenic component to conventional therapeutic modalities has generally produced modest survival benefits for cancer patients. Currently, it is unclear why these clinically available drugs targeting the same angiogenic pathways produce dissimilar effects in preclinical models and human patients. In this article, we discuss possible mechanisms of various anti-angiogenic drugs and the future development of optimized treatment regimens.

Place, publisher, year, edition, pages
SUN YAT SEN UNIV MED SCI WHO , 2016. Vol. 35, no 21
Keyword [en]
Angiogenesis; Cancer therapy; Anti-angiogenesis; Vascular endothelial growth factor; Biomarker
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-125802DOI: 10.1186/s40880-016-0084-4ISI: 000370009400002PubMedID: 26879126OAI: oai:DiVA.org:liu-125802DiVA: diva2:910327
Note

Funding Agencies|European Research Council advanced grant ANGIOFAT [250021]; Swedish Research Council; Swedish Cancer Foundation; Karolinska Institute Foundation; Karolinska Institute Distinguished Professor Award; Torsten Soderberg Foundation; Novo Nordisk Foundation; Knut and Alice Wallenberg Foundation

Available from: 2016-03-08 Created: 2016-03-04 Last updated: 2017-05-02

Open Access in DiVA

fulltext(1609 kB)168 downloads
File information
File name FULLTEXT01.pdfFile size 1609 kBChecksum SHA-512
b3ebdceb45637c83b6c49e252e79e491099d3abb2b0590d8c92948c476a249482a8364d0334f1ca9e102a44f0346fed1b4e6f738f11c9a2428a843c1cff93dd8
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Cao, Yihai

Search in DiVA

By author/editor
Cao, Yihai
By organisation
Faculty of Medicine and Health SciencesDivision of Cardiovascular Medicine
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 168 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 415 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf